The underlying inflammatory chronic disease influences infliximab pharmacokinetics-Reference-Cited by-同舟云学术

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Published:2016-09-02 Issue:7 Volume:8 Page:1407-1416
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Passot Christophe¹²,Mulleman Denis¹³,Bejan-Angoulvant Theodora¹⁴,Aubourg Alexandre⁵,Willot Stephanie⁶,Lecomte Thierry¹⁵,Picon Laurence⁵,Goupille Philippe¹³,Paintaud Gilles¹²,Ternant David¹²

Affiliation:

1. Université François Rabelais de Tours, CNRS, UMR, “Genetics, Immunotherapy, Chemistry and Cancer,” Tours, France

2. Laboratoire de Pharmacologie-Toxicologie, Tours, France

3. Service de Rhumatologie, Tours, France

4. Service de Pharmacologie Clinique, Tours, France

5. Service de Gastro-entérologie, Tours, France

6. Service de Pédiatrie, Tours, France

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2016.1216741

Reference49 articles.

1. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

2. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study

3. Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

4. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis

5. Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Obesity and Metabolic Syndrome on IBD Outcomes;Digestive Diseases and Sciences;2024-06-12

2. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models;British Journal of Clinical Pharmacology;2024-06-06

3. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

4. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

5. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease;Clinical Pharmacokinetics;2024-03-15